hemophilia gene therapy (Genetics Institute/Targeted Genetics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehemophilia gene therapy (Genetics Institute/Targeted Genetics)
Drug Alias NametgAAV-FVIIIFactor VIII gene therapy (Genetics Institute/Targeted Genetics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionCoagulation factor VIII stimulants
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth BioPharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of North Carolina, GreensboroArmata Pharmaceuticals IncWyeth BioPharma
Active IndicationsN/A
Inactive IndicationsHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A